Methimazole | Thiamazole;NSC 38608;Northyx;Favistan | 2-巯基-1-甲基咪唑 | Other Compounds | Anti-Thyroid Agent

首页 / / / / Methimazole

甲巯咪唑 /Methimazole {[allProObj[0].p_purity_real_show]}

货号：A119279 同义名： 2-巯基-1-甲基咪唑 / Thiamazole;NSC 38608

Methimazole is an antithyroid medicine.

Methimazole 化学结构
CAS号：60-56-0

Methimazole 3D分子结构
CAS号：60-56-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Methimazole 纯度/质量文件产品仅供科研

货号：A119279 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

Methimazole 生物活性

描述	Methimazole is a well-known antithyroid agent utilized primarily for the treatment and study of hyperthyroidism. Alongside its therapeutic use, methimazole is recognized for its significant hepatotoxicity, which is a major concern during its clinical application^[1].^[2].
体外研究	Furthermore, methimazole has been found to inhibit the secretion of CXC chemokine ligand 10 in human thyrocytes, highlighting its impact on immune modulation in thyroid cells^[3].

Methimazole 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00677469	Graves Disease	Not Applicable	Completed	-	Iran, Islamic Republic of ... 展开 >> Endocrine and Metabolism Research Center Shiraz, Fars, Iran, Islamic Republic of 收起 <<
NCT01977963	-		Recruiting	-	Taiwan ... 展开 >> National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Shyang-Rong Shih, PhD 886-972653337 srshih@ntu.edu.tw Principal Investigator: Shyang-Rong Shih, PhD 收起 <<
NCT00725946	Breast Cancer ... 展开 >> Breast Cancer Early Stage Breast Cancer (Stage 1-3) Breast Cancer Metastatic Breast Cancer 收起 <<	Early Phase 1	Terminated	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<

Methimazole 参考文献

[1]Tatara MR, et al. Effects of long-term oral administration of methimazole on femur and tibia properties in male Wistar rats. Biomed Pharmacother. 2017 Oct;94:124-128.

[2]Reza Heidari, et al. Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes. Drug Chem Toxicol. 2013 Oct;36(4):403-11.

[3]Crescioli C, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007 Oct;195(1):145-55.

Methimazole 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

8.76mL

1.75mL

0.88mL

43.79mL

8.76mL

4.38mL

87.59mL

17.52mL

8.76mL

Methimazole 技术信息

CAS号	60-56-0
分子式	C₄H₆N₂S
分子量	114.169

别名	2-巯基-1-甲基咪唑 ;Thiamazole;NSC 38608;Northyx;Favistan
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Room Temperature

溶解度

DMSO: 105 mg/mL(919.69 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 50 mg/mL(437.95 mM)

动物实验配方

PO 0.5% CMC-Na 40 mg/mL clear

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00677469	Graves Disease	Not Applicable	Completed	-	Iran, Islamic Republic of ... 展开 >> Endocrine and Metabolism Research Center Shiraz, Fars, Iran, Islamic Republic of 收起 <<
NCT01977963	-		Recruiting	-	Taiwan ... 展开 >> National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Shyang-Rong Shih, PhD 886-972653337 srshih@ntu.edu.tw Principal Investigator: Shyang-Rong Shih, PhD 收起 <<
NCT00725946	Breast Cancer ... 展开 >> Breast Cancer Early Stage Breast Cancer (Stage 1-3) Breast Cancer Metastatic Breast Cancer 收起 <<	Early Phase 1	Terminated	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT03303053	Hyperthyroidism ... 展开 >> Graves Disease 收起 <<	Phase 3	Recruiting	March 1, 2018	Malaysia ... 展开 >> Hospital Queen Elizabeth 2 Recruiting Kota Kinabalu, Sabah, Malaysia, 88300 Contact: Yin Khet Fung, Dr. +6 088324600 fung@doctors.org.uk Contact: Gayathri D Krishnan, Dr. +6 088324600 kgaya3@yahoo.com Sub-Investigator: Pei Lin Chan, Dr. Hospital Ampang Recruiting Ampang, Selangor, Malaysia, 68000 Contact: Vijiya M Valayatham, Dr +60342896000 ammu_vj@yahoo.com Hospital Putrajaya Recruiting Putrajaya, Wilayah Persekutuan, Malaysia, 62250 Contact: Serena SK Khoo, Dr. +6 03 83124200 sk_liv@rocketmail.com Contact: Zanariah Hussein, Dr. +6 03 83124200 zanariahh@hotmail.com Sub-Investigator: Siti A Alias, Dr Sub-Investigator: Lisa Mohamed Nor, Dr Sub-Investigator: Rashidah Bahari, Dr Sub-Investigator: Nurul Z Badarudin, Dr 收起 <<
NCT01458600	Graves´ Disease	Phase 4	Completed	-	Sweden ... 展开 >> Departmenty of Endocrinology, Skane University Hospital Malmö, Sweden Department of Endocrinology, Karolinska Hospital Stockholm, Sweden Department of Internal Medicine, section of Endocrinology, Sodersjukhuset Stockholm, Sweden 收起 <<
NCT02812888	-		Unknown	June 2017	China, Jiangsu ... 展开 >> The First People's Hospital of Xuzhou, Recruiting Xuzhou, Jiangsu, China, 221000 Contact: Zhen Zhongli, MD +86 13952200973 1973324055@qq.com Contact: Xi Jijiang, MD +86 13814429263 549932860@qq.com 收起 <<
NCT03447093	-		Recruiting	December 2021	China, Heilongjiang ... 展开 >> First affiliated hospital of Harbin medical university Recruiting Harbin, Heilongjiang, China, 150001 Contact: Yunwei Wei +86-0451-85553099 hydwyw11@hotmail.com 收起 <<
NCT01534169	Graves' Disease	Phase 1	Completed	-	China, Jiangsu ... 展开 >> Nanjing First Hospital Affiliated to Nanjing Medical University Nanjing, Jiangsu, China, 210006 收起 <<
NCT02376088	-		Completed	-	-
NCT01247077	QoL Before and After 9 Month o... 展开 >>f Medical Treatment of Graves´Thyrotoxicosis Potential Effect of Selenium 收起 <<	Phase 2	Completed	-	Sweden ... 展开 >> Jan Calissendorff, Medical clinic, Eskilstuna, Sweden Eskilstuna, Södermanland, Sweden, 63188 Emil Mikulski Eskilstuna, Sweden, 63188 收起 <<
NCT00150111	Graves´ Disease ... 展开 >> Thyroid Associated Ophthalmopathy 收起 <<	Phase 1 Phase 2	Completed	-	Denmark ... 展开 >> Department of Endocrinology, Odense University Hospital Odense, Funen, Denmark, 5000 Department of Hematology, Odense University Hospital Odense, Denmark, 5000 收起 <<
NCT00150137	Toxic Nodular Goitre ... 展开 >> Graves Disease 收起 <<	Phase 4	Completed	-	Denmark ... 展开 >> Department of Endocrinology, Odense University Hospital Odense, Funen, Denmark, 5000 收起 <<
NCT01893450	Graves Ophthalmopathy	Not Applicable	Terminated(Efficacy demonstrat... 展开 >>ed on a preliminary analysis) 收起 <<	-	Mexico ... 展开 >> Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City, Distrito Federal, Mexico, 14000 收起 <<
NCT00150124	Toxic Nodular Goitre ... 展开 >> Graves' Disease 收起 <<	Phase 4	Completed	-	Denmark ... 展开 >> Department of Endocrinology, Odense University Hospital Odense, Funen, Denmark, 5000 收起 <<
NCT02654041	Glioblastoma Multiforme (GBM)	Phase 2	Terminated(Drug manufacturer n... 展开 >>o longer could supply for study) 收起 <<	-	Israel ... 展开 >> Tel-Aviv Medical Center, Israel Tel-Aviv, Israel, 64239 收起 <<
NCT00917241	Graves' Disease	Phase 4	Completed	-	-
NCT00001421	Dermatomyositis ... 展开 >> Polymyositis 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Bethesda, Maryland, United States, 20892 收起 <<
NCT01560299	Graves Disease	Not Applicable	Completed	-	Iran, Islamic Republic of ... 展开 >> Mashad University of Medical Sciences Mashad, Khorasan Razavi, Iran, Islamic Republic of, 91766 收起 <<
NCT03433352	-		Recruiting	December 20, 2019	China, Heilongjiang ... 展开 >> First affiliated hospital of Harbin medical university Recruiting Harbin, Heilongjiang, China, 150001 Contact: Yunwei Wei +86-0451-85553099 hydwyw11@hotmail.com 收起 <<
NCT01849861	Healthy	Phase 4	Unknown	September 2014	Brazil ... 展开 >> Universidade Federal do Rio de Janeiro Recruiting Rio de Janeiro, Brazil, 21941-590 Contact: Dhiãnah SO Chachamovitz, MD +552126203063 dhianahsantini@gmail.com Contact: Patrícia de Fátima S Teixeira, MD, PhD +552125622748 pfatima@hucff.ufrj.br Principal Investigator: Dhiãnah SO Chachamovitz, MD 收起 <<
NCT02727738	Graves' Disease	Not Applicable	Completed	-	Italy ... 展开 >> Endocrinology Unit Pisa, PI, Italy, 56124 收起 <<
NCT03390582	-		Recruiting	November 1, 2021	China, Heilongjiang ... 展开 >> First affiliated hospital of Harbin medical university Recruiting Harbin, Heilongjiang, China, 150001 Contact: Yunwei Wei +86-0451-85553099 hydwyw11@hotmail.com 收起 <<

甲巯咪唑 /Methimazole {[allProObj[0].p_purity_real_show]}

Methimazole 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Methimazole 质控信息

Methimazole 生物活性

Methimazole 临床研究

Methimazole 参考文献

Methimazole 实验方案

Methimazole 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

甲巯咪唑 /Methimazole {[allProObj[0].p_purity_real_show]}

Methimazole 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Methimazole 质控信息

Methimazole 生物活性

Methimazole 临床研究

Methimazole 参考文献

Methimazole 实验方案

Methimazole 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Methimazole 纯度/质量文件产品仅供科研